SEARCH

SEARCH BY CITATION

References

  • 1
    Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:114.
  • 2
    Hampton T. Parkinson disease registry launched. JAMA 2005;293:149.
  • 3
    Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384386.
  • 4
    Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:10151022.
  • 5
    Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:3339.
  • 6
    Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet 2006;7:306318.
  • 7
    Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004;19:9971005.
  • 8
    Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55:S2S6.
  • 9
    Dewey RB, Jr. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3S7.
  • 10
    Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. Mov Disord 2004;19:2228.
  • 11
    Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: Impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001;19:10131038.
  • 12
    Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726733.
  • 13
    Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677692.
  • 14
    Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations. Mov Disord 2005;20(Suppl 11):S11S16.
  • 15
    Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: Further validation and implications for clinical trials. Mov Disord 2004;19:14091413.
  • 16
    Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:7581.
  • 17
    Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:10601065.
  • 18
    Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162168.
  • 19
    Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436441.
  • 20
    Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998;5:235242.
  • 21
    Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000:CD002261.
  • 22
    Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:10571062.
  • 23
    Perezaharon J, Abbot RJ, Playfer JR, et al. Ropinirole, a placebo-controlled study of efficacy as adjunct therapy in Parkinsonian-patients not optimally controlled on L-Dopa. Neurology 1994;44:A244.
  • 24
    Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234245.
  • 25
    Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000:CD001516.
  • 26
    Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: A 16-week bromocriptine controlled study. J Neurol 2003;250:9096.
  • 27
    Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:11081115.
  • 28
    Quinn NP, For the European and South African Rotigotine CDS Study Group. A multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of rotigotine constant delivery system (CDS) in patients with advanced Parkinson's disease. XIV International Congress on Parkinson's Disease, Helsinki (July 28-August 1), 2001.
  • 29
    LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:12621267.
  • 30
    Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513520.
  • 31
    Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2001:CD001518.
  • 32
    Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:6872.
  • 33
    Miguel F, Obeso JA, Olive Plana JM, et al. Double-blind parallel group study of the efficacy and tolerability of the cabergoline vs placebo in Parkinsonian patients with motor fluctuations. FCE Report: 21336/722i, 1993.
  • 34
    Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202212.
  • 35
    Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989;39:11091111.
  • 36
    Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:4555.
  • 37
    Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clin Neuropharmacol 1991;14:228234.
  • 38
    Ondo WG. Pooled analysis of two identical phase 3 studies of a novel selegiline preparation as adjunctive therapy for Parkinson's disease. World Parkinson Congress, Washington, DC, 2006.
  • 39
    Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426432.
  • 40
    Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 2005;62:241248.
  • 41
    Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in adjunct therapy with rasagiline given once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005;365:947954.
  • 42
    Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004:CD004554.
  • 43
    Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:3640.
  • 44
    Im JH, Jeon BS, Lee MS, Lee WY, Kim JW, Lee MC. A multicenter, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's disease experiencing end-of-dose deterioration. Mov Disord 2002;17:S40.
  • 45
    Fenelon G, Bourdeix I, Pere JJ, Galiano L, Schadrack J. Entacapone provides additional symptomatic benefits in Parkinson's disease patients treated with L-DOPA and a dopamine agonist who are experiencing wearing-off motor fluctuations: Results of a randomized, double-blind study. Neurology 2002;58:A466A467.
  • 46
    Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:10711079.
  • 47
    Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:5360.
  • 48
    Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245255.
  • 49
    Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747755.
  • 50
    Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:13091314.
  • 51
    Myllyla VV, Jackson M, Larsen JP, Baas H, for the Tolcapone International Parkinson's Disease Study (TIPS) Group Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with ’wearing-off ’ phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial. Eur J Neurol 1997;4:333341.
  • 52
    Adler CH, Singer C, O’Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:10891095.
  • 53
    Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology 1998;50:S46S53.
  • 54
    Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov Disord 1997;12:928934.
  • 55
    Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:8187.
  • 56
    Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:10661071.
  • 57
    Olanow CW, Watkins PB. Tolcapone: An efficacy and safety review (2007). Clin Neuropharmacol 2007;30:287294.
  • 58
    Cedarbaum JM, Silvestri M. Methods for assessing motor fluctuations in conducting clinical trials of antiparkinson agents. In: Clifford Rose F, editor. Parkinson's disease and the problems of clinical trials. London : Smith-Gordon, 1992;7585.
  • 59
    Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, editors. Recent developments in Parkinson's disease, 2nd ed. Florham Park , NJ : Macmillan Health Care Information, 1987;153164.
  • 60
    Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:21292170.
  • 61
    Zanni GR. Patient diaries: Charting the course. Consult Pharm 2007;22:472476, 479–482.
  • 62
    Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson's disease: A study of outpatient clinic attenders. Mov Disord 1997;12:916922.
  • 63
    Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson's disease. Mov Disord 1998;13:406413.
  • 64
    Longstreth WT, Jr., Nelson L, Linde M, Munoz D. Utility of the sickness impact profile in Parkinson's disease. J Geriatr Psychiatry Neurol 1992;5:142148.
  • 65
    Brod M, Mendelsohn GA, Roberts B. Patients’ experiences of Parkinson's disease. J Gerontol B Psychol Sci Soc Sci 1998;53:P213P222.
  • 66
    Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819827.
  • 67
    Lyons KE, Pahwa R. Electronic motor function diary for patients with Parkinson's disease: A feasibility study. Parkinsonism Relat Disord 2007;13:304307.
  • 68
    Burton C, Weller D, Sharpe M. Are electronic diaries useful for symptoms research? A systematic review. J Psychosom Res 2007;62:553561.
  • 69
    Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials 2003;24:182199.
  • 70
    Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 2001;16:7278.
  • 71
    Pahwa R, Wilkinson S, Smith D, Lyons K, Miyawaki E, Koller WC. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997;49:249253.